MDGL

Madrigal Pharmaceuticals Inc

NASDAQ· Healthcare· Biotechnology

$533.76-1.83%

Key metrics

Market cap: $12.33B
P/E: —
Forward P/E: 55.5x
P/B: 23.5x
Dividend yield: —
EPS: -$13.74
ROE: -53.31%
Profit margin: -25.32%
Revenue growth: +71.20%
Beta: -1.00
52-week high: $615.00
52-week low: $393.61

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Employees: 915
Headquarters: West Conshohocken, United States
Website: madrigalpharma.com

Company description provided by Yahoo Finance.